Skip to main content

Table 3 Adjusted mean PGWB total scores by baseline severity of heartburn symptoms

From: Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity

Trial/Follow-up

 

n

Mean (s.e.)

Clinical Trial 1

   

8 Weeks

None/Minor

59

80.5 (1.6)

 

Mild

159

80.3 (1.0)

 

Moderate

59

82.0 (1.6)

 

Severe

13

87.5 (3.5)

Clinical Trial 2

   

4 Weeks

None/Minor

237

82.4 (0.8)

 

Mild

219

81.8 (0.9)

 

Moderate

160

82.5 (1.0)

 

Severe

33

82.3 (2.2)

8 Weeks

None/Minor

234

83.4 (0.9)

 

Mild

219

82.1 (0.9)

 

Moderate

155

83.7 (1.1)

 

Severe

35

82.3 (2.3)

12 Weeks

None/Minor

231

84.4 (0.9)

 

Mild

217

83.1 (1.0)

 

Moderate

151

85.8 (1.2)

 

Severe

34

82.5 (2.4)

16 Weeks

None/Minor

229

86.0 (0.9)

 

Mild

211

84.8 (1.0)

 

Moderate

153

88.4 (1.2)

 

Severe

32

86.8 (2.5)

Clinical Trial 3

   

4 Weeks

None/Minor

40

76.0 (3.0)

 

Mild

21

73.7 (3.9)

 

Moderate

79

72.8 (2.0)

 

Severe

84

70.9 (2.0)

12 Weeks

None/Minor

37

76.9 (3.2) *

 

Mild

17

71.9 (4.5)

 

Moderate

71

74.0 (2.3)

 

Severe

69

64.3 (2.4)

24 Weeks

None/Minor

37

74.5 (3.5)

 

Mild

18

69.6 (4.8)

 

Moderate

68

72.4 (2.5)

 

Severe

74

67.4 (2.4)

  1. *p < 0.05 for test of overall differences in least square means from ANCOVA model, adjusted for gender, age, relevant baseline PGWB total score, and symptom resolution status.